Search research articles
Contact Us
Filters
Showing results (21-30 of 69) with videos related to
Page
of 7
Sort By:
European Review for Medical and Pharmacological Sciences
|
March 17, 2023
Risk factors for delirium among patients with advanced cancer in palliative care: a multicenter, patient-based registry cohort in South Korea
S W Lee, E H Jung, H J Kim, et al.
Cancer Letters
|
October 6, 1997
Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate
S Y Rha, S H Noh, H J Kwak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 15, 2008
Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
J Jeong, H-C Jeung, S Y Rha, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2008
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
H Chang, S Y Rha, H-C Jeung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2007
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up
H-C Jeung, Y W Moon, S Y Rha, et al.
British Journal of Cancer
|
February 20, 2014
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
Y Wang, T K Choueiri, J-L Lee, et al.
ESMO Open
|
April 12, 2025
Corrigendum to "An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations": [ESMO Open 10 (2025) 104106]
K H Kim, C Park, S-H Beom, et al.
ESMO Open
|
January 28, 2025
An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations
K H Kim, C Park, S-H Beom, et al.
International Journal of Molecular Medicine
|
August 10, 2000
Tissue urokinase-type plasminogen activator receptor levels in breast cancer
S J Gong, S Y Rha, H C Chung, et al.
Breast Cancer Research and Treatment
|
August 7, 1998
Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
H C Chung, S Y Rha, J O Park, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 69) with videos related to
Sort By:
Page
of 7
European Review for Medical and Pharmacological Sciences
|
March 17, 2023
Risk factors for delirium among patients with advanced cancer in palliative care: a multicenter, patient-based registry cohort in South Korea
S W Lee, E H Jung, H J Kim, et al.
Cancer Letters
|
October 6, 1997
Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate
S Y Rha, S H Noh, H J Kwak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 15, 2008
Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
J Jeong, H-C Jeung, S Y Rha, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2008
Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
H Chang, S Y Rha, H-C Jeung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2007
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up
H-C Jeung, Y W Moon, S Y Rha, et al.
British Journal of Cancer
|
February 20, 2014
Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
Y Wang, T K Choueiri, J-L Lee, et al.
ESMO Open
|
April 12, 2025
Corrigendum to "An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations": [ESMO Open 10 (2025) 104106]
K H Kim, C Park, S-H Beom, et al.
ESMO Open
|
January 28, 2025
An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations
K H Kim, C Park, S-H Beom, et al.
International Journal of Molecular Medicine
|
August 10, 2000
Tissue urokinase-type plasminogen activator receptor levels in breast cancer
S J Gong, S Y Rha, H C Chung, et al.
Breast Cancer Research and Treatment
|
August 7, 1998
Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients
H C Chung, S Y Rha, J O Park, et al.
Page
of 7